Literature DB >> 16988069

Inherited erythermalgia: limb pain from an S4 charge-neutral Na channelopathy.

Jin-Sung Choi1, Sulayman D Dib-Hajj, Stephen G Waxman.   

Abstract

BACKGROUND: Inherited erythermalgia (also termed "erythromelalgia"), characterized by episodic burning pain in the distal extremities evoked by warmth, has been causally linked with mutations of the Na(v)1.7 sodium channel, which is preferentially expressed in nociceptors. Thus far, Na(v)1.7 mutations within intracellular linker parts of the channel have been physiologically characterized.
OBJECTIVE: To investigate a Na(v)1.7 erythermalgia mutation that substitutes one uncharged amino acid for another within an S4 segment.
METHODS: Whole-cell patch-clamp analysis was used to study biophysical properties of wild-type and mutant (F216S) Na(v)1.7 channels in mammalian cells.
RESULTS: The F216S mutation hyperpolarizes the voltage dependence of activation by 11 mV, accelerates activation, slows deactivation, and enhances the response to slow, small depolarizations.
CONCLUSION: These results provide a physiologic basis for the linkage to erythermalgia of an Na(v)1.7 mutation that substitutes one uncharged residue for another within an S4 segment of the channel. These changes should increase excitability of nociceptive dorsal root ganglion neurons in which the mutant channel is present, thus contributing to pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988069     DOI: 10.1212/01.wnl.0000231514.33603.1e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  A case of primary erythermalgia with encephalopathy.

Authors:  Julien Seneschal; Guilhem Solé; Alain Taieb; Xavier Ferrer
Journal:  J Neurol       Date:  2009-06-17       Impact factor: 4.849

2.  Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation.

Authors:  Brian W Jarecki; Patrick L Sheets; James O Jackson; Theodore R Cummins
Journal:  J Physiol       Date:  2008-07-03       Impact factor: 5.182

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Between fire and ice: refractory hypothermia and warmth-induced pain in inherited erythromelalgia.

Authors:  See Wan Tham; Li Li; Philip Effraim; Stephen Waxman
Journal:  BMJ Case Rep       Date:  2017-07-26

5.  Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents.

Authors:  Jonathan W Theile; Brian W Jarecki; Andrew D Piekarz; Theodore R Cummins
Journal:  J Physiol       Date:  2010-11-29       Impact factor: 5.182

6.  Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders.

Authors:  Xiaoyang Cheng; Sulayman D Dib-Hajj; Lynda Tyrrell; Dowain A Wright; Tanya Z Fischer; Stephen G Waxman
Journal:  Mol Pain       Date:  2010-04-29       Impact factor: 3.395

7.  Autonomic dysfunction in SCN9A-associated primary erythromelalgia.

Authors:  Min-Kyeong Kim; Ji-Won Yuk; Hyang-Sook Kim; Ki-Jong Park; Dae-Seong Kim
Journal:  Clin Auton Res       Date:  2012-11-15       Impact factor: 4.435

8.  Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy.

Authors:  Munmun Chattopadhyay; Marina Mata; David J Fink
Journal:  J Neurosci       Date:  2008-06-25       Impact factor: 6.167

Review 9.  Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.

Authors:  Joost P H Drenth; Stephen G Waxman
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  A patient with adult erythermalgia: evidence suggesting an autoimmune etiology.

Authors:  Autumn L Jackson; John A Oates
Journal:  Am J Med Sci       Date:  2008-04       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.